No significant co-alterations were found in gynecologic cancer samples.<h4>Conclusions</h4>ESR1 alterations were most frequent in HR + /HER2- BC samples and missense mutations were more frequent in metastatic samples, consistent with their role in ET resistance and disease progression. This evidence concerns the gene ESR1 and breast cancer.